Vietnam Blames Deputy Minister, DAV For Broader Vaccine Approval
This article was originally published in PharmAsia News
Vietnam authorities blame a deputy minister of health and the nation's drug agency for allowing wider use of a pair of cervical cancer vaccines than generally permitted. An inspector for the Ministry of Health was ordered to look into the issue after Merck Sharp and Dohme, and GlaxoSmithKline were accused of improper lobbying to get the broader-use recommendation. The inspector said the deputy minister and the Drug Administration of Vietnam were responsible for approving Merck's Gardasil and GSK's Cervarix for women as old as 55 instead of the normal age span of 10 to 25. The deputy and DAV leaders ordered two medical councils involved to reconsider the age of users, the inspector said. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.